Altimmune, Inc.
ALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | 0% | – |
| Cost of Goods Sold | $15 | $0 | $0 | $0 |
| Gross Profit | -$15 | $0 | $0 | $0 |
| % Margin | -299,100% | 100% | 100% | 100% |
| R&D Expenses | $15 | $17 | $16 | $20 |
| G&A Expenses | $6 | $6 | $6 | $5 |
| SG&A Expenses | $6 | $6 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$15 | $0 | $0 | $0 |
| Operating Expenses | $6 | $23 | $22 | $25 |
| Operating Income | -$21 | -$23 | -$22 | -$25 |
| % Margin | -417,180% | -458,440% | -436,300% | -497,320% |
| Other Income/Exp. Net | $2 | $1 | $2 | $2 |
| Pre-Tax Income | -$19 | -$22 | -$20 | -$23 |
| Tax Expense | $0 | $0 | -$1 | $0 |
| Net Income | -$19 | -$22 | -$20 | -$23 |
| % Margin | -380,280% | -442,920% | -391,500% | -463,600% |
| EPS | -0.21 | -0.27 | -0.26 | -0.33 |
| % Growth | 22.2% | -3.8% | 21.2% | – |
| EPS Diluted | -0.21 | -0.27 | -0.26 | -0.33 |
| Weighted Avg Shares Out | 89 | 81 | 76 | 71 |
| Weighted Avg Shares Out Dil | 89 | 81 | 76 | 71 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$18 | -$22 | -$20 | -$23 |
| % Margin | -369,840% | -437,040% | -404,520% | -462,920% |